Pfizer posted lower fourth-quarter revenue and a GAAP net loss due to large non-cash impairment charges, partially offset by stable underlying performance as reflected in positive adjusted earnings.

Pfizer's Q3 2025 results showed a decline in both revenue and net income, primarily driven by reduced demand for COVID-19 products. However, cost control measures and non-COVID product growth partially offset the decline. The company raised its full-year EPS guidance, signaling confidence in ongoing performance.

Pfizer delivered a robust second quarter in 2025, with revenues reaching $14.7 billion, marking a 10% operational increase year-over-year. The company's reported diluted EPS was $0.51, while adjusted diluted EPS stood at $0.78, reflecting a 30% increase. This strong performance led Pfizer to reaffirm its full-year 2025 revenue guidance and raise its adjusted diluted EPS guidance, demonstrating confidence in its strategic execution and operational efficiency.

Pfizer posted a strong adjusted EPS and net income despite a revenue decrease driven by lower Paxlovid sales. Cost-saving initiatives and R&D productivity improvements bolstered performance.

Pfizer delivered strong Q4 2024 results, reporting $17.8 billion in revenue, a 21% year-over-year operational increase. Adjusted EPS was $0.63, up from $0.10 in Q4 2023. Growth was driven by increased sales in oncology, Eliquis, and the Vyndaqel family, though partially offset by a decline in Comirnaty revenue.

Pfizer reported a strong third quarter in 2024, marked by a 32% year-over-year operational revenue increase to $17.7 billion. Excluding Paxlovid and Comirnaty, revenues grew 14% operationally. The company raised its full-year revenue guidance to $61.0 to $64.0 billion and adjusted diluted EPS guidance to $2.75 to $2.95.

Pfizer reported a strong second quarter in 2024, marked by revenue growth and increased guidance for the full year. Revenues grew by 3% operationally year-over-year, driven by key in-line brands and recent commercial launches. The company also launched a manufacturing optimization program expected to yield $1.5 billion in cost savings by the end of 2027.

Pfizer's Q1 2024 revenues reached $14.9 billion, with a reported diluted EPS of $0.55 and an adjusted diluted EPS of $0.82. The company reaffirms its full-year 2024 revenue guidance of $58.5 to $61.5 billion and raises adjusted diluted EPS guidance to $2.15 to $2.35.

Pfizer's Q4 2023 revenues were $14.2 billion, a 41% decrease compared to Q4 2022, primarily due to a decline in Comirnaty and Paxlovid revenues. Excluding these products, revenues grew 8%. The company reported a diluted loss per share of $(0.60) and adjusted diluted EPS of $0.10. Pfizer reaffirms its full-year 2024 guidance.

Pfizer's Q3 2023 revenues decreased by 41% operationally to $13.2 billion, driven by lower sales of Paxlovid and Comirnaty, though non-COVID product revenues increased by 10%. The company reported a diluted loss per share of $(0.42), significantly impacted by $5.6 billion in non-cash inventory write-offs. Pfizer reaffirmed its full-year 2023 revenue guidance of $58.0 to $61.0 billion and adjusted diluted EPS guidance of $1.45 to $1.65. A new cost realignment program was initiated to deliver at least $3.5 billion in annual net cost savings.

Pfizer's Q2 2023 revenues were $12.7 billion, a 53% operational decrease driven by declining Paxlovid and Comirnaty revenues. Excluding these, revenues grew 5% operationally. Reported EPS was $0.41, and adjusted EPS was $0.67. The company narrowed its 2023 revenue guidance to $67-$70 billion and adjusted non-COVID operational revenue growth expectation to 6-8%.

Pfizer reported first-quarter 2023 revenues of $18.3 billion, a 26% operational decrease driven by lower Comirnaty revenue. Excluding Comirnaty and Paxlovid, revenues grew 5% operationally. Reported diluted EPS was $0.97, down 29%, and adjusted diluted EPS was $1.23, down 24%. Pfizer reaffirmed its full-year 2023 financial guidance and continued to advance new product launches.

Pfizer reported strong Q4 2022 results with revenues of $24.3 billion, reflecting 13% operational growth. Full-year 2022 revenues reached $100.3 billion, an all-time high, with reported diluted EPS of $0.87 for the quarter and $5.47 for the year.

Pfizer reported solid third-quarter results, raising the lower end of its 2022 revenue guidance and narrowing its Adjusted diluted EPS guidance. Revenue guidance for Comirnaty was raised by $2 billion, and was reaffirmed for Paxlovid.

Pfizer reported strong second-quarter results, with revenues of $27.7 billion and adjusted diluted EPS of $2.04, driven by strong contributions from Paxlovid and Comirnaty. The company raised its full-year financial guidance for revenues and adjusted diluted EPS.

Pfizer's Q1 2022 earnings showcase significant revenue growth, driven by strong performance of Comirnaty and Paxlovid. The company reaffirms its full-year financial outlook, demonstrating confidence in its portfolio and strategic direction.

Pfizer reported a strong fourth quarter with revenues of $23.8 billion, a 105% increase compared to the prior-year quarter. The company provided full-year 2022 revenue guidance of $98.0 to $102.0 billion and adjusted diluted EPS of $6.35 to $6.55. Pfizer also raised its Comirnaty revenue guidance to approximately $32 billion and issued initial Paxlovid revenue guidance of approximately $22 billion for 2022.

Pfizer reported strong Q3 2021 results with revenues of $24.1 billion, a 134% increase compared to the prior-year quarter. The company raised its full-year 2021 guidance for revenues to a range of $81.0 to $82.0 billion and adjusted diluted EPS to a range of $4.13 to $4.18.

Pfizer reported strong second-quarter 2021 results, with revenues of $19.0 billion, reflecting 86% operational growth. The company raised its full-year 2021 guidance for revenues to a range of $78.0 to $80.0 billion and adjusted diluted EPS to a range of $3.95 to $4.05.

Pfizer's Q1 2021 revenues reached $14.6 billion, reflecting a 42% operational growth. Excluding BNT162b2 vaccine revenues, the company still achieved an 8% operational growth. The company raised its full-year 2021 revenue guidance to $70.5 to $72.5 billion and adjusted diluted EPS to $3.55 to $3.65.

Pfizer's Q4 2020 revenues reached $11.7 billion, reflecting an 11% operational growth. The company's adjusted diluted EPS for Q4 2020 was $0.42. Key growth drivers included Vyndaqel/Vyndamax, Eliquis, and oncology biosimilars. Pfizer also raised its full-year 2021 guidance for adjusted diluted EPS to a range of $3.10-$3.20.

Pfizer reported a decrease in third-quarter revenues by 4% to $12.1 billion. Despite the decline, Biopharma revenues increased by 4% operationally, driven by Vyndaqel/Vyndamax, biosimilars, and key brands like Eliquis and Ibrance. The company updated and tightened its 2020 financial guidance, including a slight increase to the midpoint of Adjusted Diluted EPS.

Pfizer's Q2 2020 revenues were $11.8 billion, an 11% decrease compared to Q2 2019. Reported diluted EPS was $0.61, while adjusted diluted EPS was $0.78. The company raised its 2020 financial guidance for revenues and adjusted diluted EPS. The COVID-19 pandemic had an estimated net unfavorable impact of approximately $500 million on Q2 2020 revenues.

Pfizer reported Q1 2020 revenues of $12.0 billion, an 8% decrease compared to Q1 2019. Biopharma grew 12% operationally, while Upjohn declined 37%. Reported EPS was $0.61, and adjusted EPS was $0.80. The company reaffirmed its 2020 financial guidance.